Valeria Faccenda

🧠 Fusion uncertainty is real...even “perfect” expert fusions can differ. Quantifying operator variability is key to define a probabilistic GS and benchmarking automatic registration vs human performance 🧮 @EFOMP_org @fisica_medica #SRS #automatism 👉🏻physicamedica.com/article/S1120-…

🔍Check out a post-hoc analysis of the ABRUPT trial on the 🔗between ☢️ RT dose to pelvic substructures & late GU TOX ⛔️ bladder trigone D1cc ≥20.3 Gy ⛔️ NVB D0.035 cc ≥23.6 Gy ➡️doi.org/10.1016/j.ctro… #prostatecancer @OncoAlert @oncodaily @urotoday

🙏 Huge credit to all speakers, moderators and colleagues who made the 1️⃣#prostateSBRTMonza 🇮🇹Symposium a great success🤩 #ProstateCancer @ESTRO_RT @ISRSy @airo_young

🚀 Join us for the 1st symposium on prostate SBRT. Medical physicists are welcome too! 📅 5–6 February 2026 📍 Hotel de la Ville, Monza 🔗 tinyurl.com/sbrt2026 Don’t miss this chance to learn and discuss with experts in the field. @ESTRO_RT @ISRSy @fisica_medica @AIRO

AIRO 2025 couldn’t have been better! 🔹 Presented the #POPART data (again 🤭) 🔹 Elected Board Member & Secretary of the GU Study Group 🔹 Awarded the AIRO Young Scholarship for an ESTRO School Feeling grateful, inspired and ready for the next steps 🚀 #AIRO2025 #RadOnc

💥 #AIRO2025: 3 days of updates in cutting-edge treatments… yet the best one is still us❗️💪🏻 #radonc @unimib @AIROyoung

📢 NRGGU005 Phase III: 698 pts with intermediate-risk #ProstateCancer RCT; SBRT (n=353) vs M-IMRT (n=345) ✅ SBRT → better bowel HRQOL (MCID 35% vs 44%, p=0.03) ⚖️No diff in urinary HRQOL; EPIC continence favours SBRT ❌futile for DFS; IMRT had ⬇️3-yr biochemical failure (4.2% vs 7.8%) SBRT safe, better QoL, ⁉️but not superior for DFS #ASTRO25 #RadOnc #PCSM

#astro25 @NRGonc Rtog 0924 trial on 2500 patients testing whole pelvic RT. Negative trial -OS no difference -PCSM no difference -DM no difference -BCR was not SS different with only 4% difference at 10 years. -toxicity increased 3 cooperative group trials now negative: getug01, Rtog 9413, Rtog 0924. Goodbye WPRT

What a great honor and privilege to deliver 2️⃣ oral presentations at #ASTRO25 Special 🙏 to @Fefe_Ferrario @valefacc22 @riccardo_ray @panizza @CiroFranzese1 #prostatecancer #abrupt #popart @urotoday @oncodaily @airo_young

@StAr_MCM74 @Fefe_Ferrario @riccardo_ray @Panizza @CiroFranzese1 @urotoday @oncodaily @airo_young 👏🏻👏🏻👏🏻 huge satisfaction!! 🎊

🇨🇦 Single-fraction lung SBRT results from British Columbia further support this as a great treatment option for stage I NSCLC. #ASTRO25 poster.astro.org/astro/2025/67t…

🚫 In >2400 men with unfavourable risk #ProstateCancer, whole-pelvic RT (WPRT) ❌ did not improve 10-yr OS or DFS vs prostate-only RT (68% both arms). 🔹 PC-specific survival 98% 🔹 Slight ↓ in biochemical failure with WPRT 🔹 More grade 2 GI adverse events ⁉️how to reconcile with POP-RT trial in PSMA era? Lower risk cohort? #ASTRO25 #RadOnc

🚀 POPART trial (n=100): Post-op SABR (32.5 Gy/5fx) for BCR after prostatectomy ✅ well-tolerated; late ≥G2 GU 7.5%, GI 1% 📉 2-yr BRFS ~79% (PSA ↓ to 0.028 ng/mL) ➡️SBRT prostate bed salvage = promising, needs longer follow-up. #ASTRO25 #RadOnc @ASTRO_org

🇩🇪🍺💙

📢“One Voice for Radiotherapy” One voice to champion access, awareness, and appreciation of the vital role radiotherapy plays in cancer care❗️ #OneVoiceForRadiotherapy #WRAD #WorldRTDay @ESTRO_RT @ASTRO_org @AIROyoung @airo_young

🚨When you squeeze your intrafraction motion data and end up changing the margins to 4 mm iso! Didn’t even remember writing this paper back at the end of last year… but just in time for some pleasant holiday reading, you can finally check it out ⤵️⤵️⤵️

📌 POPART🇮🇹 confirms salvage SBRT to PB is well tolerated at 20-month median FUP in 100pts + ✅1-year BRFS of 90% and ⚠️ISUP as significant predictor of recurrence (HR=1.59; p=0.035) ⏭️Waiting for next steps #ProstateCancer #salvageSBRT @oncodaily @OncoAlert #PostOp ⤵️⤵️⤵️

What better way to celebrate the end of two agonizing months preparing for the permanent job exam than sailing along the Ligurian coast? Okay, maybe sailing in the Pacific Ocean would’ve been better.....but on Monday, it's back to work 🙃🎊

Me right before a deadline

Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data sciencedirect.com/science/articl… This systematic review and meta-analysis by the DADSPORT Collaboration evaluated the impact of hormone therapy (HT) added to postoperative radiotherapy (RT) in nonmetastatic #ProstateCancer across five randomized controlled trials involving 4,411 participants. While HT did not significantly improve overall survival (OS) in the general population, it did show meaningful benefits in metastasis-free survival (MFS) and prostate cancer–specific survival (PCSS), each with a 4% absolute improvement at 8 years. Notably, OS benefits may be limited to patients with higher pre-RT PSA levels or CAPRA-S scores. These findings support the use of adjuvant HT to improve cancer outcomes, particularly in higher-risk patients. @DrSpratticus @AmarUKishan @drjefstathiou @PCaParker @_APollack @PaulSargos @felixfengmd @OncoAlert @Silke_Gillessen @AOmlin @nataliagandur @bavilima